PMC7248319_01
PMC7248319_02
PMC7248319_03
Clinical course of patient 1.
fmed-07-00241-g0001.jpg
PMC7248319_03_fmed-07-00241-g0001.jpg
F1
Patient 3 (Figures 1-3). Pneumonia developed 8, 12, and 7 days after the onset of illness in Patients 1, 2, and 3, respectively (Figure 4; P1A, P2A, and P3A).
Clinical course of patient 2.
fmed-07-00241-g0002.jpg
PMC7248319_03_fmed-07-00241-g0002.jpg
F2
Patient 3 (Figures 1-3). Pneumonia developed 8, 12, and 7 days after the onset of illness in Patients 1, 2, and 3, respectively (Figure 4; P1A, P2A, and P3A).
Clinical course of patient 3. BT, body temperature; CT, computed tomographic scan; CXP, chest X-ray photograph; Neg, negative PCR test; PCR, polymerase chain reaction test for COVID-19 nucleic acid; Pos, positive PCR test; RV, reference value.
fmed-07-00241-g0003.jpg
PMC7248319_03_fmed-07-00241-g0003.jpg
F3
Patient 3 (Figures 1-3). Pneumonia developed 8, 12, and 7 days after the onset of illness in Patients 1, 2, and 3, respectively (Figure 4; P1A, P2A, and P3A).
Initial computed tomographic images of patients 1 (P1), 2 (P2), and 3 (P3) with COVID-19 pneumonia (A) and those after treatment with Lopinavir/Ritonavir (B).
fmed-07-00241-g0004.jpg
PMC7248319_03_fmed-07-00241-g0004.jpg
F4
Patient 3 (Figures 1-3). Pneumonia developed 8, 12, and 7 days after the onset of illness in Patients 1, 2, and 3, respectively (Figure 4; P1A, P2A, and P3A).